Trial · NCT02593110

Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

NCT02593110, Not applicable, Completed, Northwestern University; results first posted 2023-01-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease. Trials, record NCT02593110. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02593110

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease
NCT number: NCT02593110
Status: Completed
Phases: Not applicable
Enrollment: 114 participants, actual
Lead sponsor: Northwestern University
Conditions: Peripheral Artery Disease
Interventions: Supervised Treadmill Exercise Therapy, Telmisartan, "No exercise" control group, Placebo
First posted: 2015-10-30
Last updated: 2023-01-11
Results first posted: 2023-01-11

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Six-minute Walk Performance	Change from baseline to six-month follow-up	We will determine whether telmisartan therapy with or without exercise improves six-minute walk distance at 6-month follow-up, compared to placebo with or without exercise (i.e. two group comparisons of all participants randomized to telmisartan vs. all participants randomized to placebo).
Secondary	Maximal Treadmill Walking Distance	Change from baseline to six-month follow-up	In the treadmill walking test, participants walk on either a gardner or modified gardner protocol until they stop the test. Distance walked is recorded.
Secondary	Walking Impairment Questionnaire (WIQ) Distance Score	Change from baseline to six-month follow-up	The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed and stair-climbing. They are scored on a 0-100 scale and that 100 indicates the best possible score.
Secondary	SF-36 Physical Functioning Score	Change from baseline to six-month follow-up	The SF-36 physical functioning score will be used to measure quality of life. They are scored on a 0-100 scale and that 100 indicates the best possible score.
Secondary	Walking Impairment Questionnaire (WIQ) Speed Score	Change from baseline to six-month follow-up	The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed and stair-climbing. They are scored on a 0-100 scale and that 100 indicates the best possible score.
Secondary	Walking Impairment Questionnaire (WIQ) Stair-climbing Score	Change from baseline to six-month follow-up	The WIQ is a well validated questionnaire that measures patient-reported walking limitations in distance and speed and stair-climbing. They are scored on a 0-100 scale and that 100 indicates the best possible score.

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Six-minute Walk Performance	Change from baseline to six-month follow-up	meters	MEAN
SECONDARY	Maximal Treadmill Walking Distance	Change from baseline to six-month follow-up	meters	MEAN
SECONDARY	Walking Impairment Questionnaire (WIQ) Distance Score	Change from baseline to six-month follow-up	score on a scale	MEAN
SECONDARY	SF-36 Physical Functioning Score	Change from baseline to six-month follow-up	score on a scale	MEAN
SECONDARY	Walking Impairment Questionnaire (WIQ) Speed Score	Change from baseline to six-month follow-up	score on a scale	MEAN
SECONDARY	Walking Impairment Questionnaire (WIQ) Stair-climbing Score	Change from baseline to six-month follow-up	score on a scale	MEAN

Source ClinicalTrials.gov

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Six-minute Walk Performance	Telmisartan + Supervised Treadmill Exercise Therapy	5.86	Standard Deviation 67.21	meters
Six-minute Walk Performance	Telmisartan + No Exercise Control Group	-3.92	Standard Deviation 47.33	meters
Six-minute Walk Performance	Placebo + Supervised Treadmill Exercise Therapy	30.27	Standard Deviation 29.44	meters
Six-minute Walk Performance	Placebo + No Exercise Control Group	-4.62	Standard Deviation 42.54	meters
Maximal Treadmill Walking Distance	Telmisartan + Supervised Treadmill Exercise Therapy	207.99	Standard Deviation 150.44	meters
Maximal Treadmill Walking Distance	Telmisartan + No Exercise Control Group	66.21	Standard Deviation 226.81	meters
Maximal Treadmill Walking Distance	Placebo + Supervised Treadmill Exercise Therapy	176.64	Standard Deviation 259.51	meters
Maximal Treadmill Walking Distance	Placebo + No Exercise Control Group	80.96	Standard Deviation 178.73	meters
Walking Impairment Questionnaire (WIQ) Distance Score	Telmisartan + Supervised Treadmill Exercise Therapy	8.77	Standard Deviation 26.35	score on a scale
Walking Impairment Questionnaire (WIQ) Distance Score	Telmisartan + No Exercise Control Group	6.33	Standard Deviation 33.69	score on a scale

1 to 10 of 24Source ClinicalTrials.gov

See all 24 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Telmisartan + Supervised Treadmill Exercise Therapy	30
Overall Study	STARTED	Telmisartan + No Exercise Control Group	29
Overall Study	STARTED	Placebo + Supervised Treadmill Exercise Therapy	28
Overall Study	STARTED	Placebo + No Exercise Control Group	27
Overall Study	COMPLETED	Telmisartan + Supervised Treadmill Exercise Therapy	30
Overall Study	COMPLETED	Telmisartan + No Exercise Control Group	26
Overall Study	COMPLETED	Placebo + Supervised Treadmill Exercise Therapy	24
Overall Study	COMPLETED	Placebo + No Exercise Control Group	25
Overall Study	NOT COMPLETED	Telmisartan + Supervised Treadmill Exercise Therapy	0
Overall Study	NOT COMPLETED	Telmisartan + No Exercise Control Group	3

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events136

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Increase in shortness of breath	General disorders	Telmisartan + Supervised Treadmill Exercise Therapy	7	30	11
other	Increase in shortness of breath	General disorders	Telmisartan + No Exercise Control Group	9	29	16
other	Increase in shortness of breath	General disorders	Placebo + Supervised Treadmill Exercise Therapy	7	28	13
other	Increase in shortness of breath	General disorders	Placebo + No Exercise Control Group	10	27	14
other	New chest pain during exertion	General disorders	Telmisartan + Supervised Treadmill Exercise Therapy	2	30	5
other	New chest pain during exertion	General disorders	Telmisartan + No Exercise Control Group	4	29	4
other	New chest pain during exertion	General disorders	Placebo + Supervised Treadmill Exercise Therapy	3	28	3
other	New chest pain during exertion	General disorders	Placebo + No Exercise Control Group	2	27	2
other	Sinus discomfort or congestion	General disorders	Telmisartan + Supervised Treadmill Exercise Therapy	20	30	54
other	Sinus discomfort or congestion	General disorders	Telmisartan + No Exercise Control Group	14	29	46

1 to 10 of 136Source ClinicalTrials.gov

See all 136 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Telmisartan + Supervised Treadmill Exercise Therapy	0	30
Total, all-cause mortality	Telmisartan + No Exercise Control Group	0	29
Total, all-cause mortality	Placebo + Supervised Treadmill Exercise Therapy	1	28
Total, all-cause mortality	Placebo + No Exercise Control Group	0	27
Total, other adverse events	Telmisartan + Supervised Treadmill Exercise Therapy	20	30
Total, other adverse events	Telmisartan + No Exercise Control Group	15	29
Total, other adverse events	Placebo + Supervised Treadmill Exercise Therapy	23	28
Total, other adverse events	Placebo + No Exercise Control Group	18	27
Total, serious adverse events	Telmisartan + Supervised Treadmill Exercise Therapy	4	30
Total, serious adverse events	Telmisartan + No Exercise Control Group	5	29

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
36194220	DERIVED	PubMed
42035974	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01HL126117	TELmisartan plus EXercise to improve functioning in PAD: The TELEX Trial	MCDERMOTT, MARY MCGRAE	NORTHWESTERN UNIVERSITY AT CHICAGO	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2015 to 2019

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02593110

GET https://conductscience.org/api/trials/v1/NCT02593110/results?page=2

API reference For AI assistants